Downregulation of c-Myc expression confers sensitivity to CHK1 inhibitors in hematologic malignancies
出版年份 2021 全文链接
标题
Downregulation of c-Myc expression confers sensitivity to CHK1 inhibitors in hematologic malignancies
作者
关键词
-
出版物
ACTA PHARMACOLOGICA SINICA
Volume -, Issue -, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2021-03-29
DOI
10.1038/s41401-021-00652-1
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Novel CHK1 inhibitor MU380 exhibits significant single-agent activity in TP53-mutated chronic lymphocytic leukemia cells
- (2019) Miroslav Boudny et al. HAEMATOLOGICA
- Discovery of (R)-5-((5-(1-methyl-1H-pyrazol-4-yl)-4-(methylamino)pyrimidin-2-yl)amino)-3-(piperidin-3-yloxy)picolinonitrile, a novel CHK1 inhibitor for hematologic malignancies
- (2019) Lexian Tong et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- From checkpoint to checkpoint: DNA damage ATR/Chk1 checkpoint signalling elicits PD-L1 immune checkpoint activation
- (2018) Kent W. Mouw et al. BRITISH JOURNAL OF CANCER
- DUOXA1-mediated ROS production promotes cisplatin resistance by activating ATR-Chk1 pathway in ovarian cancer
- (2018) Yunxiao Meng et al. CANCER LETTERS
- NFYB-induced high expression of E2F1 contributes to oxaliplatin resistance in colorectal cancer via the enhancement of CHK1 signaling
- (2018) Zejun Fang et al. CANCER LETTERS
- Prexasertib, a cell cycle checkpoint kinase 1 and 2 inhibitor, in BRCA wild-type recurrent high-grade serous ovarian cancer: a first-in-class proof-of-concept phase 2 study
- (2018) Jung-Min Lee et al. LANCET ONCOLOGY
- Investigational CHK1 inhibitors in early stage clinical trials for acute myeloid leukemia
- (2018) Kamal Chamoun et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Checkpoint kinase 1 is essential for normal B cell development and lymphomagenesis
- (2017) Fabian Schuler et al. Nature Communications
- c-Myc Alteration Determines the Therapeutic Response to FGFR Inhibitors
- (2016) Hongyan Liu et al. CLINICAL CANCER RESEARCH
- CHK1 as a therapeutic target to bypass chemoresistance in AML
- (2016) Laure David et al. Science Signaling
- CHK1 as a therapeutic target to bypass chemoresistance in AML
- (2016) Laure David et al. Science Signaling
- c-Myc Alterations Confer Therapeutic Response and Acquired Resistance to c-Met Inhibitors in MET-Addicted Cancers
- (2015) Aijun Shen et al. CANCER RESEARCH
- Chk1 phosphorylated at serine345 is a predictor of early local recurrence and radio-resistance in breast cancer
- (2015) Nouf Alsubhi et al. Molecular Oncology
- Inhibition of the checkpoint kinase Chk1 induces DNA damage and cell death in human Leukemia and Lymphoma cells
- (2014) Christopher Bryant et al. Molecular Cancer
- Differential response of normal and malignant urothelial cells to CHK1 and ATM inhibitors
- (2014) W-T Wang et al. ONCOGENE
- CHK1 overexpression in T-cell acute lymphoblastic leukemia is essential for proliferation and survival by preventing excessive replication stress
- (2014) L M Sarmento et al. ONCOGENE
- MYC Regulation of CHK1 and CHK2 Promotes Radioresistance in a Stem Cell-like Population of Nasopharyngeal Carcinoma Cells
- (2012) W.-J. Wang et al. CANCER RESEARCH
- Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells
- (2012) Wanjuan Yang et al. NUCLEIC ACIDS RESEARCH
- Therapeutic Implications for the Induced Levels of Chk1 in Myc-Expressing Cancer Cells
- (2011) A. Hoglund et al. CLINICAL CANCER RESEARCH
- Chk1 is essential for chemical carcinogen-induced mouse skin tumorigenesis
- (2011) L M Tho et al. ONCOGENE
- RNAi screen of the protein kinome identifies checkpoint kinase 1 (CHK1) as a therapeutic target in neuroblastoma
- (2011) K. A. Cole et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started